Anal adenocarcinoma complicating chronic Crohn’s disease

Ioannis Papaconstantinou a, Dionysios S. Mantzos a,∗, Agathi Kondi-Pafiti b, Ioannis E. Koutroubakis c

a 2nd Department of Surgery, Aretaieion Hospital, Medical School, University of Athens, 76 V. Soias Avenue, 11528, Athens, Greece
b Department of Pathology, Aretaieion Hospital, Medical School, University of Athens, 76 V. Soias Avenue, 11528, Athens, Greece
c Department of Gastroenterology, University Hospital of Heraklion, 71003 Heraklion, Crete, Greece

Abstract

Introduction: Colorectal adenocarcinoma and Crohn’s disease are known to be associated entities. However, a carcinoma arising within a chronic perianal fistulous tract in a patient with Crohn’s disease is a rare complication.

Presentation of case: We present a case of a 40-year-old male patient with a long-standing perianal Crohn’s disease who developed an anal mucinous adenocarcinoma within the fistulous tracts.

Discussion: Although, Crohn’s disease and colorectal carcinoma association is well established, few cases have been reported where the cancer has originated within a perianal fistula. Constant mucosal regeneration occurring within a fistula seems to be the predominant pathogenetic mechanism, while immunosuppressants and anti-TNF agents may also contribute to the malignant transformation. Unfortunately, the lack of suspicion and the inadequate physical examination or colonoscopy due to exacerbation of the perianal symptoms could lead to delayed diagnosis; and thus, a poor prognosis.

Conclusion: Albeit a rare complication, clinicians should maintain a high degree of vigilance about the possible development of adenocarcinoma in patients with long-standing perianal Crohn’s disease. Thus, these patients should be kept under regular surveillance with examination under anaesthesia and biopsies or curettage of the tracts.

Introduction

The association between Crohn’s disease (CD) and colorectal cancer is well established. However, carcinoma associated with chronic fistulous CD is a rare complication. We report a case of a 40-year-old CD patient who developed an anal adenocarcinoma within a long-standing perianal fistulous tract and review the available literature.

Presentation of case

A 40-year-old male patient with ileocolonic CD and perianal fistulising lesions, diagnosed 23 years ago, was referred to our institution for a new finding of soft tissue within a perianal fistula. His past medical history included loop sigmoidostomy and review of the available literature.

1. Introduction

2. Presentation of case

http://dx.doi.org/10.1016/j.ijscr.2015.04.013
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
abdominoperineal resection, where a 37 cm segment of colon with the mesorectum, anal canal of 7 cm and the corresponding overlying soft tissue of the perineum was resected. On histopathology, a T4N1 moderately/poorly differentiated mucinous adenocarcinoma was detected (Fig. 3). According to the referrer, his last physical examination, six months prior to admission, was unremarkable. Unfortunately, three months postoperatively the patient developed multiple bone metastases and he is currently receiving chemotherapy.

3. Discussion

Up to 43% of CD patients will develop perianal fistulising disease [1]. The development of carcinoma within a chronic perianal fistula is a rare complication of CD, first reported by Lightdale et al. in 1975 [2]. Iesalnieks et al. has reported 65 cases with anorectal cancer associated with perianal fistulae in patients with CD [3] with an estimated incidence of 0.3–0.7% [4].

The pathogenesis has not yet been fully elucidated; Traube at al. suggested that the environment of constant mucosal regeneration occurring within a fistula may cause dysplastic changes, which may ultimately lead to adenocarcinoma [5]. On the contrary, Church et al. supported that a fistula formation may be a result of the cancer itself [6]. In the present case, the pre-existence of long-standing fistulae renders the latter improbable. It has been suggested that immunosuppressants and anti-TNF agents may contribute to the malignant transformation [7]. In a recent article, Österman et al. supported that patients treated with combination of adalimumab and immunomodulators were more likely to develop cancer compared both to general population and patients with adalimumab monotherapy [8]. This plausible pathogenetic mechanism may hold true in the present case, where the patient had been treated with anti-TNF and immunomodulators for approximately ten years prior to the diagnosis of cancer.

Patients with long-standing CD, diagnosed before thirty years of age and with faecal diversion are at greater risk for the development of carcinoma arising in association with a perianal fistula [9]. Unfortunately, the majority of these patients have poor prognosis due to the advanced disease stage at diagnosis. Similarities between benign deterioration of the perianal symptoms and de novo development of cancer, as well as the lack of a high degree of suspicion for this rare complication may be responsible for the delay of diagnosis. Furthermore, the exacerbation of the symptoms makes physical examination or colonoscopy cumbersome to occur. A complex, long-standing fistula requires thorough examination of the rectum and the perianal area under anaesthesia followed by biopsies and/or curettage of the fistulous tracts. It follows, those patients with chronic perianal fistulising CD should be kept under a regular and careful surveillance. Ogawa et al. have suggested that a patient should undergo surveillance for carcinoma after seven years of perianal disease [4].

The gold standard treatment of fistulae-associated anal adenocarcinoma in patients with CD is abdominoperineal resection. In a recent article, Gaertner et al. reported that all patients with perianal adenocarcinoma who had undergone neoadjuvant chemoradiation therapy followed by abdominoperineal resection had a complete response [10]. The potential benefits of this kind of therapy have not yet been established; and therefore, in our patient we proceeded only to surgical treatment.

4. Conclusion

Clinicians who manage patients with long-standing perianal CD should maintain high level of suspicion for adenocarcinoma development on the setting of perianal fistulising CD. A chronic, complex fistulous disease may conceal a tumour and the examination under anaesthesia with biopsies and/or curettage of the fistulous tracts

Fig. 1. Fistulous orifices at 7 and 11 o’clock.

Fig. 2. MRI of adenocarcinoma developing within fistulous tracts (high signal intensity on T2-weighted image).

Fig. 3. Histological section of perianal fistulous tract infiltrated by moderately–poorly differentiated mucus–producing adenocarcinoma (haematoxylin–eosin × 100).
may be warranted. Therefore, all patients suffering from chronic perianal CD should be kept under regular surveillance.

**Conflict of interest**

All authors declare that there is no financial arrangement or other relationship that could be construed as a conflict of interest.

**Funding**

There was not involvement of study sponsors in this work.

**Authors contribution**

Papaconstantinou I. conceived of the study, carried out its design and the critical revision for important intellectual content and had the overall responsibility of the manuscript.

Mantzos S.D. carried out the design, the collection, analysis and interpretation of the data and drafted the manuscript.

Kondi-Pafiti A. provided some of the data and participated in the critical revision.

Koutroubakis I. conceived of the study, participated in the design and carried out the critical revision.

All authors read and approved the final manuscript.

**Consent**

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

**Acknowledgements**

We would like to express our very great appreciation to Mr Mylonas S.N. MD, of the Vascular Unit of Aretaieion Hospital, as well as Mr Elissaios Kontis MD and Mr Spyropoulos B.G. MD of the 2nd Department of Surgery of Aretaieion Hospital, for their valuable advice regarding to the final form of this manuscript.

**References**

[1] E.V. Loftus Jr, R.R. Cima, Inflammatory bowel disease, in: C.J. Yeo, J.B. Matthews, D.W. Mc Fadden, J.H. Pemberton, J.H. Peters (Eds.), Shackelford’s Surgery of the Alimentary Tract, 7th edition, Philadelphia: Elsevier, 2013, pp. 1966–1968.

[2] C.J. Lightdale, S.S. Sternberg, G. Posner, P. Sherlock, Carcinoma complicating Crohn’s disease. Report of seven cases and review of the literature, Am. J. Med. 59 (1975) 262–268.

[3] I. Iesalnieks, W.B. Gaertner, H. Glass, U. Strauch, M. Hipp, A. Agha, et al., Fistula-associated anal adenocarcinoma in Crohn’s disease, Inflamm. Bowel Dis. 16 (2010) 1643–1648.

[4] H. Ogawa, S. Haneda, C. Shibata, K. Miura, M. Nagao, S. Ohnuma, et al., Adenocarcinoma associated with perianal fistulas in Crohn’s disease, Anticancer Res. 33 (2013) 685–689.

[5] J. Traube, S. Simpson, R.H. Riddell, B. Levin, J.B. Kirsner, Crohn’s disease and adenocarcinoma of the bowel, Digest. Dis. Sci. 25 (1980) 939–944.

[6] J.M. Church, F.L. Weakley, V.W. Fazio, B.A. Sebek, E. Achkar, M. Carwell, The relationship between fistulas in Crohn’s disease and associated carcinoma: report of four cases and a review of the literature, Dis. Colon Rectum 28 (1985) 361–366.

[7] C.S. Ball, R. Wujanto, N.Y. Haboubi, P.F. Schofield, Carcinoma in anal Crohn’s disease: discussion paper, J. R. Soc. Med. 81 (1988) 217–219.

[8] M.T. Osterman, W.J. Sandborn, J.F. Colombel, A.M. Robinson, W. Lau, B. Huang, et al., Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease, Gastroenterology 146 (2014) 941–949.

[9] Y. Tokunaga, H. Sasaki, T. Saito, Carcinoma in anorectal fistulas of Crohn’s Disease with seton drainage case report and review of the literature, Digestion 77 (2008) 20–21.

[10] W.B. Gaertner, G.F. Hagerman, C.O. Finne, M. Alavi, J. Jessurun, D.A. Rothenberger, et al., Fistula-associated anal adenocarcinoma: good results with aggressive therapy, Dis. Colon Rectum 51 (2008) 1061–1067.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.